Emerging-Trends-in-the-Monoclonal-Antibody-Therapy-Market

Monoclonal antibody therapy represents a significant advancement in targeted treatment, playing a transformative role in fields such as oncology, immunology, and the management of infectious diseases. These monoclonal antibodies (mAbs) are specifically engineered proteins that simulate the immune system’s natural ability to combat harmful pathogens, including viruses, and to identify and neutralize specific cells associated with diseases. Unlike conventional therapies that may impact both healthy and diseased cells, monoclonal antibody therapy is highly specific, targeting unique antigens present on the surface of cancer cells or other abnormal cells. This specificity greatly enhances treatment outcomes while reducing collateral damage to healthy tissue.